MIST

Milestone Pharmaceuticals, Inc. · NASDAQ

Sector Health Technology
Industry Pharmaceuticals: Major
Website milestonepharma.com
Employees(FY) 39
ISIN CA59935V1076

Performance

+8.7%

+38.89%

+40.85%

+33.33%

+19.76%

YTD

-41.0%

Profile

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. Milestone Pharmaceuticals Inc. has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

Advanced Technical Analysis

Technical Analysis of MIST 2024-12-02

The stock exhibits a strong bullish sentiment with a Moving Average Score of 96, indicating robust upward momentum, while the Technical Score of 76 further supports this positive outlook. However, the Oscillators Score of 56 suggests a more neutral stance, indicating potential consolidation or a pause in the upward trend.

Technical Scores and Rating

Moving Average Score

Oscillator Score

Technical Rating

Stock Analysis of MIST

Stock Rank

Recent News & Updates

2024-11-24 19:00
Milestone Pharmaceuticals to Present at the Piper Sandler 36th Annual Healthcare Conference(Globenewswire)
2024-11-18 20:55
After Golden Cross, Milestone Pharmaceuticals (MIST)'s Technical Outlook is Bright(Yahoo Finance)
2024-11-11 20:17
Milestone Pharmaceuticals: Q3 Earnings Snapshot(Yahoo Finance)
2024-11-11 20:03
Milestone Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Regulatory and Corporate Update(Globenewswire)
2024-09-23 20:00
Milestone Pharmaceuticals to Host Investor KOL Event(Globenewswire)
2024-09-05 19:00
Milestone Partner Ji Xing Pharmaceuticals Ltd Announces Positive Topline Results from the Phase 3 Study of Etripamil in PSVT in China(Globenewswire)
2024-09-03 20:00
Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors(Globenewswire)
2024-09-02 20:00
Milestone Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference(Globenewswire)
2024-08-25 20:00
Milestone Pharmaceuticals to Present Data on Etripamil at the ESC Congress 2024(Globenewswire)
2024-08-08 04:41
Milestone Pharmaceuticals: Q2 Earnings Snapshot(Yahoo Finance)
2024-08-08 04:17
Milestone Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Regulatory and Corporate Update(Globenewswire)
2024-07-30 20:00
MilestoneÂ® Pharmaceuticals to Present at the Upcoming BTIG Virtual Biotechnology Conference(Yahoo Finance)
2024-07-14 20:00
Milestone Pharmaceuticals Refreshes Board of Directors(Globenewswire)
2024-06-11 20:00
Milestone Pharmaceuticals to Host KOL Event for Investors Learnings from the Field: Expert Perspectives on PSVT in the Community Setting on June 20, 2024(Globenewswire)
2024-05-30 20:00
Milestone Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference(Globenewswire)
2024-05-28 19:00
Milestone Pharmaceuticals Announces FDA Acceptance of New Drug Application for CARDAMYST(Globenewswire)
2024-05-21 20:00
Milestone Pharmaceuticals Partners with Arrhythmia Alliance on SVT Awareness(Globenewswire)
2024-05-16 00:00
Milestone Pharmaceuticals (MIST) Upgraded to Buy: Here's What You Should Know(Zacks)
2024-05-13 01:53
MIST Stock Earnings: Milestone Pharmaceuticals Beats EPS for Q1 2024(Investorplace)
2024-05-12 19:15
Milestone Pharmaceuticals: Q1 Earnings Snapshot(Yahoo Finance)
2024-05-12 19:15
Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update(Globenewswire)
2024-05-01 20:00
Milestone Pharmaceuticals Announces Data Presentations on Etripamil at Heart Rhythm 2024, 2024 Stanford BioDesign Arrhythmia Technologies Retreat, and ISPOR 2024(Globenewswire)
2024-04-16 20:00
Milestone Pharmaceuticals to Present Data on Etripamil at the Preventative Cardiovascular Nursing Symposium(Globenewswire)
2024-04-07 23:36
Milestone Pharmaceuticals Announces Etripamil Data Demonstrating Patients' Ability to Self-Manage Recurring PSVT, Presented at The American College of Cardiology Annual Meeting(Globenewswire)
2024-04-02 20:00
Milestone Pharmaceuticals to Present at the 23rd Annual Needham Healthcare Conference(Globenewswire)
2024-03-31 20:00
Milestone Pharmaceuticals to Present Data on Etripamil at the American College of Cardiology and European Heart Rhythm Association Annual Conferences(Globenewswire)
2024-03-27 19:00
Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia(Globenewswire)
2024-03-21 01:53
MIST Stock Earnings: Milestone Pharmaceuticals Misses EPS for Q4 2023(Investorplace)
2024-03-20 19:14
Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Regulatory and Corporate Update(Globenewswire)
2024-02-29 03:01
Milestone Pharmaceuticals to Participate in a Corporate Panel Discussion at TD Cowen 44th Annual Health Care Conference(Globenewswire)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment. Kavout and its partners are participants in a number of affiliate advertising programs. As an Amazon Associate, Kavout or its partners earn from qualifying purchases from affiliate links. We also participate in other affiliate and advertising programs that provide a means for us to earn advertising fees by advertising and linking to third-party websites.